为了庆祝约翰逊和约翰逊创新的开幕 -jlabs@ Washington, DC门，我们很荣幸能开球In-Depth Conversations with Residentsseries to introduce you to our inaugural class of resident companies.
在由于患病并发症而导致家庭成员丧生之后，首席执行官德尔·史密斯（Del Smith）与首席发展官蒂法尼·惠特洛（Tiffany Whitlow）合作，发现Acclinate是Acclinate蓝骑士™company at JLABS @ Washington, DC company aiming to increase diversity in clinical trials to achieve more inclusive research that reflects all populations.
Read on to learn how Acclinate seeks to work with underserved communities to build trust in healthcare and underscore the importance of clinical trials in our first installment ofIn-Depth Conversations with Residents。
问：告诉我们您公司背后的故事。Acclinate建立背后的个人和科学灵感是什么？
DS: When I was younger, my mom, a home healthcare worker, contracted tuberculosis. The doctors gave her drug after drug trying to determine which one was going to be most effective. Unfortunately, she passed away from complication of the illness. I then set on a path to find my biological father, only to learn that he passed away a year prior from cancer. The greater surprise was that he and every single male on his side of the family died from cancer before the age of 50.
这些经验种植了种子的载体，并希望找到方法，以更好地吸引与健康相关的问题，包括临床试验作为治疗方案。43％的美国人口被认为是非白人，但非裔美国人仅占临床试验参与者的5％，而西班牙裔美国人则占1％。1,2Lack of clinical trial diversity is a major problem for both minority communities and pharmaceutical companies.
这个问题的大部分源于颜色社区对医学界（特别是医学研究）的不信任。在Acclinate，我们将文化和技术整合在一起，通过与与健康相关的问题进行互动，同时也向他们展示了参加可能是治疗方案的临床试验的机会，从而帮助弥合这种鸿沟。
问：为什么成立医疗保健或生命科学公司？如果您在视力中取得成功，您希望您的影响对患者有何影响？
DS: COVID-19 put a spotlight on the health disparities that has always existed in our country. We are on a mission to do our part to advance health equity and ensure more inclusive health research. The time is now. Our technology uses AI/ML to identify diverse individuals who are most likely to take part in a particular trial. Because we are seen as a trusted source, we are able to provide biopharmaceutical companies, clinical research organizations, and academic medical centers with more diverse leads that convert to enrolled trial participants.
There has never been so much attention placed on ensuring inclusivity of the life science community. I am encouraged by the many initiatives being led by major stakeholders. However, time will tell if what we are seeing is mostly rhetoric or a decision to invest the resources necessary to truly impact change. When it comes to more inclusive clinical research, I anticipate that a significant shift will likely happen once the U.S. FDA mandates that clinical trial data be representative.
问：您是否遇到了创造初创企业的任何障碍？您会向早期企业家提供什么建议？是什么使您成为我们今天看到的创新者？
DS：虽然我有健康信息系统的背景，但我的职业生涯不在临床试验空间中 - 我不是“来自系统”。早期，今天仍然在某种程度上，该行业将其指出为负面。但是，大多数变革性和破坏性的商业模式都来自不是“来自系统”的创新者。
知道这一点，我们不仅必须构建一个有效的解决方案，而且还必须花时间说服行业有更好的方法。我对其他早期企业家的建议是不要让“谁是谁”或“这就是我们一直这样做的方式”的格言是对将您的解决方案推向市场的威慑力量。
Q: Why did you want to become a part of Johnson & Johnson Innovation – JLABS (“JLABS”)? What are you hoping to achieve as a JLABS @ Washington, DC resident company?
DS：我们需要将自己沉浸在诸如Johnson＆Johnson家族公司在努力实现其考验中的多样性时面临的讨论和挑战。乐动体育意甲直播我们还需要验证和进一步完善我们的算法，用于预测谁最有可能参加特定试验。作为JLABS @ Washington，DC的居民，我们可以访问一个网络来完成两者。我们对迄今为止的进步感到满意，必须感谢JLABS @ Washington，DC及其团队的JLABS负责人Sally Allain获得了我们获得的支持和指导。
For more on Acclinate, visit:https://www.acclinate.com
Johnson & Johnson Innovation - JLABS @ Washington, DC is open for business. Learn more and join us in pursuit of accelerating innovation in service of our patients:https://jji.jnjinnovation.com/join-jlabs-dc。
1https://www.cnn.com/2021/08/12/politics/us-census-2020-data/index.html
2https://www.fda.gov/files/science%20＆％20 research/publish/paublish/white-paper-on-the-dialogues-on-dialogues-on-diversifying-clinical-trials-conference.pdf
免责声明
在这个博客是信息的信息purposes only. The information is either proprietary or licensed to Johnson & Johnson Innovation LLC, its parent company or any subsidiaries or affiliate companies ("JJI") or is provided by or proprietary to third parties. In case of third-party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, JJI does not endorse these third parties or any of the information provided in this email. By providing the information in this blog, JJI does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in this email and is not responsible for any use by or alterations of this information by you. JJI hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this blog.